Mild to moderate depression with symptoms of stagnation of liver qi and spleen deficiency Mental and Behavioural Disorders Depressive episode
Conditions
Interventions
The 108 eligible participants will be allocated to the experimental or placebo arm based on a random lottery. Participants will be required to take the medicine twice daily for four consecutive weeks
Sponsors
Beijing University of Chinese Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Meet the Diagnostic Statistics Manual of Mental Disorders (DSM-5) regarding the diagnosis of mild to moderate depression 2. A score between 20 and 35 on HAMD 3. Meet the TCM criteria of liver depression and spleen deficiency syndrome 4. Aged between 16 - 18 years old, both genders 5. Patients agree to participate in this trial and assign the informed consent 6. Capable of reading and follow-up treatment, and permanently live locally
Exclusion criteria
Exclusion criteria: 1. Bipolar depression,treatment-resistant depression and severe suicidal risk 2. History of bipolar disorder, schizophrenia, obvious psychotic symptoms and depression disorder caused by non-addictive substances 3. Combine with severe cardiovascular diseases, cerebrovascular diseases, hepatic diseases, renal diseases, hematological disease, cancer, or other severe primary diseases 4. Pregnant or lactating women 5. Inability to finish the compliance test, judge the efficacy and have complete data 6. Involved with any other clinical trial at the time of consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Depression with symptoms of stagnation of liver qi and spleen deficiency, assessed using the Hamilton Depression scale (HAMD) at baseline, 1 week, 2 weeks and 4 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall health measured using TCM symptoms Scale at baseline, 1 week, 2 weeks and 4 weeks | — |
Countries
China
Contacts
Public ContactZhe Xue
Outcome results
None listed